Group 1 - The core viewpoint of the article is that Suzhou Ailong Technology Co., Ltd. is expected to turn a profit in 2025, with a projected net profit attributable to the parent company ranging from RMB 14.96 million to RMB 22.44 million, marking a significant increase compared to the previous year [1] - The expected net profit represents an increase of RMB 36.66 million to RMB 44.14 million compared to the previous year's legally disclosed data, indicating a year-on-year growth of 168.93% to 203.39% [1] - The main reasons for the performance change include the company's focus on its core business, optimization of product structure, increased sales of traditional Chinese medicine intelligent products and pharmaceutical information products, as well as efforts to reduce costs, enhance profitability, and improve management [1]

证券代码：688329 证券简称：艾隆科技 公告编号：2026-002 （2）归属于母公司所有者扣除非经营性损益后的净利润为人民币642万元到 962万元，与上年同期法定披露数据相比，将增加4,451.28万元至4,771.28万元， 同比增长116.85%-125.25%。 二、上年同期业绩情况 （一）利润总额：-2,440.07万元。归属于母公司所有者的净利润：-2,170.34 万元。归属于母公司所有者的扣除非经常性损益的净利润：-3,809.28万元。 苏州艾隆科技股份有限公司 2025 年年度业绩预盈公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 2025年1月1日至2025年12月31日。 （二）业绩预告情况 （1）经财务部门初步测算，预计苏州艾隆科技股份有限公司(以下简称"公 司")2025年年度实现归属于母公司所有者的净利润与上年同期（法定披露数据） 相比，将实现扭亏为盈，实现归属于母公司所有者净利润为人民币1,496万元至 2,244万元，与上年同期法定披露 ...

Core Viewpoint - The company, Ailong Technology, expects a significant increase in net profit for the year 2025, projecting a range of 14.96 million to 22.44 million yuan, which represents a year-on-year growth of 168.93% to 203.39% [1] Group 1 - The company continues to focus on its core business and optimize its product structure [1] - There has been an increase in sales of traditional Chinese medicine intelligent products and pharmaceutical information technology products [1] - The company has implemented cost reduction and profit enhancement measures, as well as improved collection and management practices, contributing to profit growth [1]

Group 1 - The core viewpoint of the article highlights the recent performance and financial metrics of Ailong Technology (688329), indicating a slight decline in stock price and mixed capital flow on January 29, 2026 [1][2] - Ailong Technology reported a main revenue of 280 million yuan for the first three quarters of 2025, reflecting a year-on-year increase of 25.12% [2] - The company experienced a net profit attributable to shareholders of -959,000 yuan, which is an improvement of 96.56% year-on-year [2] Group 2 - In Q3 2025, Ailong Technology achieved a single-quarter main revenue of 149 million yuan, marking an impressive year-on-year increase of 83.53% [2] - The net profit attributable to shareholders for Q3 2025 was 7.43 million yuan, showing a significant year-on-year increase of 182.09% [2] - The company operates in the field of intelligent management of medical supplies, providing comprehensive solutions through smart management devices and software platforms for healthcare institutions [2]

Core Viewpoint - Ailong Technology (688329) reported a revenue increase of 25.12% year-on-year for the first three quarters of 2025, indicating strong growth in the medical supplies management sector [2]. Financial Performance - For the first three quarters of 2025, Ailong Technology achieved a main business revenue of 280 million yuan, with a net profit attributable to shareholders of -959,000 yuan, an improvement of 96.56% year-on-year [2]. - The third quarter of 2025 saw a single-quarter main business revenue of 149 million yuan, reflecting an 83.53% year-on-year increase, and a net profit attributable to shareholders of 7.43 million yuan, up 182.09% year-on-year [2]. - The company reported a gross profit margin of 45.79% and a debt ratio of 42.74% [2]. Market Activity - As of January 28, 2026, Ailong Technology's stock closed at 24.27 yuan, down 0.37%, with a turnover rate of 1.53% and a trading volume of 11,800 hands, amounting to a transaction value of 28.73 million yuan [1]. - The net outflow of main funds was 1.0035 million yuan, accounting for 3.49% of the total transaction value, while retail investors saw a net inflow of 3.43 million yuan, representing 11.94% of the total transaction value [1].

证券日报网讯1月27日，艾隆科技在互动平台回答投资者提问时表示，截至2026年1月20日，公司股东持 有人数(已合并)5152户。 ...

Core Viewpoint - The joint issuance of the policy by nine departments aims to promote high-quality development in the pharmaceutical retail industry, focusing on various dimensions such as improving pharmaceutical services, innovating health services, and optimizing industry structure, which will inject strong momentum into the digital transformation of the sector [1][2] Group 1: Policy Impact - The policy mandates pharmaceutical retail enterprises to accurately collect and verify drug traceability codes during sales, enhancing drug traceability management and application, thereby improving medication safety supervision and risk control of medical insurance funds [1] - The policy emphasizes the need for digitalization and intensive transformation in the pharmaceutical retail industry, which is expected to release concentrated demand for these changes [2] Group 2: Company Positioning - Ailong Technology (688329.SH) is positioned to benefit from the policy due to its strong foundation in smart pharmacy, smart wards, smart storage, and pharmaceutical information, which allows it to fully leverage the policy dividends and open up new growth spaces [1] - The company has developed the "Drug 4π All-Dimensional Spherical Scanning System," which achieves comprehensive recognition of traceability codes and meets the upgraded traceability management needs of retail pharmacies, already receiving high recognition in practical use [1] - Ailong Technology has established a comprehensive scene system covering material management within hospitals, achieving domestic substitution of core equipment and reaching international leading technical standards, thus forming a complete product line from single products to overall solutions [2] Group 3: Market Potential - The company's full series of dispensing machines align precisely with the policy's requirements for traceability management, enabling automatic collection and association of traceability code information during prescription dispensing, thus creating a new paradigm of unmanned traceability code collection in the industry [2] - The products and services of Ailong Technology have been validated by over a thousand medical institutions, indicating significant potential for expansion in the retail sector as the policy details gradually take effect [2] - With its first-mover advantage, the company is expected to capture market share and enhance its performance growth momentum as the policy is implemented [2]

Core Viewpoint - Ailong Technology (688329) reported a revenue increase of 25.12% year-on-year for the first three quarters of 2025, indicating strong growth in the medical supplies management sector [2]. Financial Performance - For the first three quarters of 2025, Ailong Technology achieved a main business revenue of 280 million yuan, with a net profit attributable to shareholders of -959,000 yuan, showing a year-on-year increase of 96.56% [2]. - The third quarter of 2025 saw a single-quarter main business revenue of 149 million yuan, up 83.53% year-on-year, and a net profit attributable to shareholders of 7.43 million yuan, reflecting a year-on-year increase of 182.09% [2]. - The company reported a gross profit margin of 45.79% and a debt ratio of 42.74% [2]. Market Activity - As of January 22, 2026, Ailong Technology's stock closed at 24.51 yuan, down 0.61%, with a turnover rate of 1.72% and a trading volume of 13,300 hands, amounting to a transaction value of 32.5 million yuan [1]. - On January 22, the net outflow of main funds was 2.58 million yuan, accounting for 7.94% of the total transaction value, while retail investors saw a net inflow of 2.25 million yuan, representing 6.94% of the total transaction value [1].

证券日报网讯 1月13日，艾隆科技在互动平台回答投资者提问时表示，截至2025年12月31日，公司股东 持有人数（已合并）5027户。 （文章来源：证券日报） ...

证券日报网讯 1月13日，艾隆科技在互动平台回答投资者提问时表示，截至2026年1月10日，公司股东 持有人数（已合并）5275户。 （文章来源：证券日报） ...